ArticleCureus2025
Breaking the Diagnostic Barrier: DNAJB9 Heat Shock Protein Testing for Fibrillary Glomerulonephritis in Cases With Low Tissue Reserves.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibrillary glomerulonephritis (FGN) is an uncommon primary glomerular condition with a vague clinical presentation that poses a diagnostic challenge. We present a case of a 73-year-old white female with severe kidney damage, malignant hypertension, and recurring abdominal pain who underwent a series of extensive tests until her renal biopsy showed eosinophilic deposits with mesangial matrix and GBM growth, indicating segmental membranoproliferative characteristics, and global mesangial proliferation of the glomeruli with fibrillary deposits. The DNAJB9 heat-shock protein was present in the tissue sample, supporting the FGN diagnosis. The lack of clear-cut treatment standards makes managing FGN difficult, and the disease has a dismal prognosis with a 50% possibility of developing end-stage renal disease within an average of 10 years post-diagnosis. Improving patient outcomes and halting further decline in renal function depend on early detection and effective care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.